Literature DB >> 1974432

Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors.

C L Broekkamp1, J S De Graaf, A M van Delft.   

Abstract

trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H- dibenz[2,3:6,7]oxepinol[4,5-c]pyrrolidine maleate (Org 5222) is a new compound with effects on animal behaviour indicating strong antipsychotic potential based on antagonism of dopaminergic and serotonergic effects. The compound inhibits apomorphine-induced climbing behaviour, mouse locomotor activity, rat activity in an open field, shuttle box behaviour in rats, pergolide induced circling in 6-hydroxydopamine(6-OHDA) lesioned rats, serotonin agonist-induced forepaw treading, head shakes and penile erections. The compound is less effective in inducing catalepsy, and antagonising SKF-38393 (tetrahydro- 1-phenyl-1H-3-benzazepine-7,8-diol HCl)-induced circling in 6-OHDA-lesioned rats and it does not induce perioral movements in rats. Based on these data and the neurochemical profile of the compound it was decided that this compound merits clinical investigation in a programme aiming for an effective antipsychotic agent with reduced risks of extrapyramidal side-effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974432

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

Review 1.  Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors:  Arpi Minassian; Jared W Young
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

2.  The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine.

Authors:  A R Cools; E P Prinssen; B A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

3.  Asenapine.

Authors:  Herbert Y Meltzer; Argyris Dritselis; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

4.  Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

Authors:  Olivia Frånberg; Charlotte Wiker; Monica M Marcus; Asa Konradsson; Kent Jardemark; Björn Schilström; Mohammed Shahid; Erik H F Wong; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2007-10-17       Impact factor: 4.530

5.  Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.

Authors:  Olivia Frånberg; Monica M Marcus; Vladimir Ivanov; Björn Schilström; Mohammed Shahid; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2009-02-07       Impact factor: 4.530

6.  Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability.

Authors:  D C Hoffman; H Donovan
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

Review 7.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.